Madrigal Pharmaceuticals, Inc. (MDGL)
Automate Your Wheel Strategy on MDGL
With Tiblio's Option Bot, you can configure your own wheel strategy including MDGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDGL
- Rev/Share 42.7204
- Book/Share 26.8646
- PB 16.2962
- Debt/Equity 0.588
- CurrentRatio 4.0149
- ROIC -0.3158
- MktCap 9942832562.0
- FreeCF/Share -8.4701
- PFCF -52.3252
- PE -34.0689
- Debt/Assets 0.2813
- DivYield 0
- ROE -0.4376
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MDGL | Barclays | -- | Overweight | -- | $964 | Jan. 28, 2026 |
| Downgrade | MDGL | Wolfe Research | Outperform | Peer Perform | -- | -- | Jan. 6, 2026 |
| Upgrade | MDGL | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Nov. 5, 2025 |
| Upgrade | MDGL | BofA Securities | Underperform | Neutral | -- | $445 | Nov. 3, 2025 |
| Initiation | MDGL | Truist | -- | Buy | -- | $580 | Oct. 15, 2025 |
| Resumed | MDGL | H.C. Wainwright | -- | Buy | -- | $500 | Sept. 4, 2025 |
| Upgrade | MDGL | B. Riley Securities | Neutral | Buy | $236 | $422 | Feb. 28, 2025 |
| Reiterated | MDGL | H.C. Wainwright | -- | Buy | $400 | $405 | Feb. 27, 2025 |
News
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's Phase 3 trial aims to expand Rezdiffra's label to early cirrhosis by 2027, with EMA approval expected in mid-2025. GLP-1s like semaglutide and tirzepatide show promising MASH results, potentially disrupting Rezdiffra's market despite its first-mover advantage.
Read More
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Read More
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target.
Read More
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights.
Read More
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
Read More
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.
Read More
About Madrigal Pharmaceuticals, Inc. (MDGL)
- IPO Date 2007-02-06
- Website https://www.madrigalpharma.com
- Industry Biotechnology
- CEO William J. Sibold
- Employees 528